Amyotrophic Lateral Sclerosis
Released: December 22, 2020
Defense Health Program
Department of Defense Amyotrophic Lateral Sclerosis Research Program
Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
The Fiscal Year 2021 (FY21) Defense Appropriations Bill has not been signed into law. Although FY21 funds have not been appropriated for the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP), the ALSRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.
The FY21 Defense Appropriations Act is anticipated to provide $40M to the Department of Defense ALSRP to support innovative and high-impact research into the development of effective treatments for Amyotrophic Lateral Sclerosis. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
Subject to the FY21 Congressional appropriation for ALSRP funding, FY21 ALSRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Therapeutic Development Award||Independent investigators at all academic levels (or equivalent)||
|Therapeutic Idea Award||Independent investigators at all academic levels (or equivalent)||
|Clinical Development Award||Independent investigators at all academic levels (or equivalent)||
|NEW! Therapeutic/Biomarker Pilot Trial Award||Independent investigators at or above the level of Assistant Professor (or equivalent)||
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Tuesday, December 22, 2020